COVID-2019 Alert

The latest information about the 2019 Novel Coronavirus, including vaccine clinics for children ages 6 months and older.

La información más reciente sobre el nuevo Coronavirus de 2019, incluidas las clínicas de vacunación para niños de 6 meses en adelante.


Lauren Kushner, MD

  • Lauren Elizabeth Kushner


Infectious Diseases

Work and Education

Professional Education

UC Irvine College of Medicine, Orange, CA, 06/30/2017


Stanford University Pediatric Residency at Lucile Packard Children's Hospital, Palo Alto, CA, 06/30/2020


Stanford University Pediatric Infectious Disease Fellowship, Stanford, CA, 07/06/2023

Board Certifications

Pediatrics, American Board of Pediatrics

All Publications

Successful nasoenteric administration of glecaprevir/pibrentasvir for donor-derived hepatitis C in two young adult heart transplant recipients at a pediatric transplant center. Pediatric transplantation Kushner, L. E., Puckett, L., Lee, J., Joerger, T., Chen, S. F., Profita, E. 2022: e14360

View details for DOI 10.1111/petr.14360

View details for PubMedID 35854405

Vaccine-Associated Measles Encephalitis in Immunocompromised Child, California, USA. Emerging infectious diseases Costales, C., Sahoo, M. K., Huang, C., Guimaraes, C. V., Born, D., Kushner, L., Gans, H. A., Doan, T. A., Pinsky, B. A. 2022; 28 (4): 906-908


We report a fatal case of vaccine-associated measles encephalitis in an immunocompromised child in California, USA. The infection was confirmed by whole-genome RNA sequencing of measles virus from brain tissue. We observed biased matrix-gene hypermutation consistent with persistent measles virus central nervous system infection.

View details for DOI 10.3201/eid2804.212357

View details for PubMedID 35318930

"For COVID" or "With COVID": Classification of SARS-CoV-2 Hospitalizations in Children. Hospital pediatrics Kushner, L. E., Schroeder, A. R., Kim, J., Mathew, R. 2021

View details for DOI 10.1542/hpeds.2021-006001

View details for PubMedID 34011566

Assessment of Sensitivity and Specificity of Patient-Collected Lower Nasal Specimens for Sudden Acute Respiratory Syndrome Coronavirus 2 Testing. JAMA network open Altamirano, J. n., Govindarajan, P. n., Blomkalns, A. L., Kushner, L. E., Stevens, B. A., Pinsky, B. A., Maldonado, Y. n. 2020; 3 (6): e2012005

View details for DOI 10.1001/jamanetworkopen.2020.12005

View details for PubMedID 32530469

Oral Antibiotics for Treating Children With Community-Acquired Pneumonia Complicated by Empyema. Clinical pediatrics Kushner, L. E., Nieves, D. J., Osborne, S., Vora, H., Arrieta, A., Singh, J. 2019: 9922819850494


No consensus exists on management of children with community-acquired pneumonia complicated by empyema (CAP-Em). We evaluated outpatient oral (O-Abx) compared with parenteral antibiotics (OPAT) in children with CAP-Em. We also evaluated inflammatory markers to guide length of treatment. We conducted a retrospective cohort study of patients discharged (2006-2016) with CAP-Em. Primary outcome measured was treatment success (no change in antibiotics or readmission to hospital for treatment of CAP-Em). White blood cell (WBC) count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) serial measurements were identified. Success was achieved in 133/144 (92.4%) O-Abx and 7/12 (58%) OPAT patients ( P = .0031). WBC and CRP decreased early; and ESR increased initially (admit and switch to O-Abx) and decreased by end of treatment. O-Abx is the modality of choice for treatment of CAP-Em after hospital discharge. WBC and CRP are useful to monitor success of O-Abx switch; and ESR provides guidance for length of treatment.

View details for DOI 10.1177/0009922819850494

View details for PubMedID 31122051

Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients JOURNAL OF VIRAL HEPATITIS Jain, M. K., Adams-Huet, B., Terekhova, D., Kushner, L. E., Bedimo, R., Li, X., Holodniy, M. 2015; 22 (1): 25-36


Chronic viral infections lead to persistent immune activation, which is alleviated by eradicating or suppressing the infection. To understand the effects of interferon treatment on immune system activation by chronic infections, we evaluated kinetic patterns of a broad spectrum of serum biomarkers during HCV treatment in HIV/HCV co-infected patients. HCV viral load and 50 biomarkers were analysed at baseline and 27 time points during pegylated interferon-alpha and ribavirin (IFN/RBV) treatment of 12 HIV/HCV co-infected patients. We evaluated biomarker changes from baseline for each time point and biomarker correlations with clinical parameters, treatment response and liver histopathology. IL-1, IL-12p40, IL-1RA, IP-10, MIG, MIP-1/1, HGF, sCD40L, TRAIL and leptin increased in the first day. IL-12p70, IL-17A, IL-10, GRO, IL-8, MCP-3, IL-4 and M-CSF peaked later during week 1. IL-1, HGF, IP-10, MIP-1, TRAIL, sCD40L, IL-10, IL-12p70, MCP-3, FGFb, ENA-78, TGF-, IL-2, IFN-, IL-6, IL-15, IL-7 and PDGF-BB decreased below baseline over the course of treatment. Higher BMI, baseline HCV viral load and leptin levels were associated with lack of sustained virologic response. ENA-78 was associated with sustained viral response. Positive correlations were found between liver inflammation and baseline CD4 count, sVCAM and HGF; fibrosis stage and HGF; liver steatosis, BMI and leptin. Our findings suggest IFN/RBV treatment initially increases levels of several biomarkers, but eventually leads to a decline in many immune markers. These findings shed light on the relationship between IFN treatment and immune activation by chronic viral infections, such as HCV.

View details for DOI 10.1111/jvh.12226

View details for Web of Science ID 000346826600005

View details for PubMedID 24506344

A feasibility study to determine if minimally trained medical students can identify markers of chronic parasitic infection using bedside ultrasound in rural Tanzania WORLD JOURNAL OF EMERGENCY MEDICINE Barsky, M., Kushner, L., Ansbro, M., Bowman, K., Sassounian, M., Gustafson, K., Lahham, S., Joseph, L., Fox, J. C. 2015; 6 (4): 293-298


Parasitic infections pose a significant health risk in developing nations and are a major cause of morbidity and mortality worldwide. In the Republic of Tanzania, the CDC estimates that 51.5% of the population is infected with one or more intestinal parasites. If diagnosed early, the consequences of chronic parasitic infection can potentially be avoided.Six first-year medical students were recruited to enroll patients in the study. They underwent ten hours of formal, hands-on, ultrasound which included basic cardiac, hepatobiliary, renal, pulmonary and FAST scan ultrasound. A World Health Organization protocol with published grading scales was adapted and used to assess for pathology in each patient's liver, bladder, kidneys, and spleen.A total of 59 patients were enrolled in the study. Students reported a sensitivity of 96% and specificity of 100% for the presence of a dome shaped bladder, a sensitivity and specificity of 100% for bladder thickening, a sensitivity and specificity of 100% for portal hypertension and ascites. The sensitivity was 81% with a specificity of 100% for presence of portal vein distention. The sensitivity was 100% with a specificity of 90% for dilated bowel.Ultrasound has shown a promise at helping to identify pathology in rural communities with limited resources such as Tanzania. Our data suggest that minimally trained first year medical students are able to perform basic ultrasound scans that can identify ultrasonographic markers of parasitic infections.

View details for DOI 10.5847/wjem.j.1920-8642.2015.04.008

View details for Web of Science ID 000382242900008

View details for PubMedID 26693265

View details for PubMedCentralID PMC4677073

Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PloS one Kushner, L. E., Wendelboe, A. M., Lazzeroni, L. C., Chary, A., Winters, M. A., Osinusi, A., Kottilil, S., Polis, M. A., Holodniy, M. 2013; 8 (4)

View details for DOI 10.1371/journal.pone.0060387

View details for PubMedID 23593207